Identifying the quality markers and optimizing the processing of Gastrodiae rhizoma to treat brain diseases

• Published in: Frontiers in pharmacology 2024-11, Vol.15, p.1396825
• Main Authors: Fu, Yan, Xu, Qingqing, Zhang, Jinqiang, Kang, Chuanzhi, Yang, Changgui, Guo, Lumei, Zhang, Chenggang, Zhou, Tao, Xiao, Chenghong
• Format: Article
• Language: English
• Subjects: fresh-cut processing; Gastrodia elata BL; metabolomics; network pharmacology; neuroprotection; Pharmacology; quality markers
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2024.1396825

Gastrodiae rhizoma (GR) refers to the dried tuber of Bl. and has been used for many centuries to treat brain diseases, such as Alzheimer's disease, major depressive disorder, and cerebral ischemia. However, the processing of GR is complex and varied, resulting in unstable clinical treatment effects. The processing protocols significantly affect the active ingredients and curative effects of GR. We can optimize the processing of GR by identifying quality markers to treat brain diseases. Fresh tubers of Bl. were processed under eight different protocols, and their resulting contents of potentially bioactive compounds were compared using liquid chromatography mass spectrometry to screen the potential quality markers of GR through stoichiometric analysis. The potential quality markers of GR targeting Alzheimer's disease, major depressive disorder, and cerebral ischemia were identified by network pharmacology, and the potentially neuroprotective effects of these components were validated through simulated docking to likely protein targets. Finally, a fit degree analysis was carried out using different composition ratios and proportions of the disease component degree value, and the therapeutic effects of different processing methods on Alzheimer's disease, major depressive disorder, and cerebral ischemia were outlined clearly. We identified 32 potential therapeutic components and screened 13 quality markers in GR, of which five quality markers (galactinol, glucosyringic acid, parishins C and E, and S-(4-hydroxybenzyl)-glutathione) showed efficacy against all three brain diseases. Furthermore, steaming and microwave-drying during processing can optimize the components of these quality markers for treating the three diseases. Processing protocols significantly affect the therapeutic components of GR and may also impact its effectiveness in treating brain diseases. Accordingly, optimizing the processing methods of GR to correspond to different therapeutic purposes may improve its efficacy against brain diseases.